Michael Hauptmann

List of Publications by Year
in descending order

173	11,359	30070 54	31849 101
papers	citations	h-index	g-index

178	178	178	14539
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Response to Klar and Adams. Journal of the National Cancer Institute, 2022, 114, 167-168.	6.3	0
2	Impact of Reverse Causation on Estimates of Cancer Risk Associated With Radiation Exposure From Computerized Tomography: A Simulation Study Modeled on Brain Cancer. American Journal of Epidemiology, 2022, 191, 173-181.	3.4	8
3	Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast, 2022, 61, 98-107.	2.2	6
4	Review of the risk of cancer following low and moderate doses of sparsely ionising radiation received in early life in groups with individually estimated doses. Environment International, 2022, 159, 106983.	10.0	34
5	Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients. British Journal of Cancer, 2022, 126, 1401-1409.	6.4	11
6	Pointing a FINGER at the contribution of lifestyle to cardiovascular events and dementia. European Heart Journal, 2022, 43, 2062-2064.	2.2	3
7	Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. Journal of Clinical Oncology, 2022, 40, 2361-2374.	1.6	45
8	Cancer risks among studies of medical diagnostic radiation exposure in early life without quantitative estimates of dose. Science of the Total Environment, 2022, 832, 154723.	8.0	17
9	Late Mortality in Childhood Cancer Survivors according to Pediatric Cancer Diagnosis and Treatment Era in the Dutch LATER Cohort. Cancer Investigation, 2022, 40, 413-424.	1.3	8
10	Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2â€“ Early Breast Cancer. Journal of Clinical Oncology, 2022, 40, 2557-2567.	1.6	49
11	The risk of cancer following high, and very high, doses of ionising radiation. Journal of Radiological Protection, 2022, 42, 020518.	1.1	1
12	Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer. Breast Cancer Research and Treatment, 2021, 185, 817-830.	2.5	2
13	Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study. Breast Cancer Research and Treatment, 2021, 185, 205-214.	2.5	19
14	Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study). JMIR Research Protocols, 2021, 10, e24414.	1.0	9
15	Dose Estimation for the European Epidemiological Study on Pediatric Computed Tomography (EPI-CT). Radiation Research, 2021, 196, 74-99.	1.5	17
16	Hearing loss among elderly people and access to hearing aids: a cross-sectional study from a rural area in Germany. European Archives of Oto-Rhino-Laryngology, 2021, 278, 5093-5098.	1.6	4
17	Change in cognition before and after nonâ€central nervous system cancer diagnosis: A populationâ€based cohort study. Psycho-Oncology, 2021, 30, 1699-1710.	2.3	2
18	Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients. Journal of the National Cancer Institute, 2021, 113, 1506-1514.	6.3	6

#	Article	IF	Citations
19	Methodological improvements to meta-analysis of low dose rate studies and derivation of dose and dose-rate effectiveness factors. Radiation and Environmental Biophysics, 2021, 60, 485-491.	1.4	5
20	Response to â€œOn the choice of methodology for evaluating dose-rate effects on radiation-related cancer risksâ€•by Walsh et al.. Radiation and Environmental Biophysics, 2021, 60, 515-516.	1.4	1
21	Sex Differences in Clinical Course and Intensive Care Unit Admission in a National Cohort of Hospitalized Patients with COVID-19. Journal of Clinical Medicine, 2021, 10, 4954.	2.4	8
22	Trajectories of Cognitive Function Prior to Cancer Diagnosis: A Population-Based Study. Journal of the National Cancer Institute, 2020, 112, 480-488.	6.3	14
23	Predicting and implications of target volume changes of brain metastases during fractionated stereotactic radiosurgery. Radiotherapy and Oncology, 2020, 142, 175-179.	0.6	15
24	Breast Implant Prevalence in the Dutch Female Population Assessed by Chest Radiographs. Aesthetic Surgery Journal, 2020, 40, 156-164.	1.6	20
25	Heart failure after treatment for breast cancer. European Journal of Heart Failure, 2020, 22, 366-374.	7.1	28
26	Epidemiological Studies of Low-Dose Ionizing Radiation and Cancer: Summary Bias Assessment and Meta-Analysis. Journal of the National Cancer Institute Monographs, 2020, 2020, 188-200.	2.1	97
27	Epidemiological Studies of Low-Dose Ionizing Radiation and Cancer: Rationale and Framework for the Monograph and Overview of Eligible Studies. Journal of the National Cancer Institute Monographs, 2020, 2020, 97-113.	2.1	39
28	Dose-volume effects of breast cancer radiation therapy on the risk of second oesophageal cancer. Radiotherapy and Oncology, 2020, 151, 33-39.	0.6	13
29	Estimates of the number of patients with high cumulative doses through recurrent CT exams in 35 OECD countries. Physica Medica, 2020, 76, 173-176.	0.7	50
30	Statistical analysis of longitudinal data on tumour growth in mice experiments. Scientific Reports, 2020, 10, 9143.	3.3	8
31	Evaluation of Confounding and Selection Bias in Epidemiological Studies of Populations Exposed to Low-Dose, High-Energy Photon Radiation. Journal of the National Cancer Institute Monographs, 2020, 2020, 133-153.	2.1	23
32	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics, 2020, 107, 837-848.	6.2	39
33	Clinical course and factors associated with outcomes among 1904 patients hospitalized with COVID-19 in Germany: an observational study. Clinical Microbiology and Infection, 2020, 26, 1663-1669.	6.0	98
34	Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer. Npj Breast Cancer, 2020, 6, 60.	5.2	9
35	Brain structure prior to non-central nervous system cancer diagnosis: A population-based cohort study. NeuroImage: Clinical, 2020, 28, 102466.	2.7	3
36	Design of the PROstate cancer follow-up care in Secondary and Primary hEalth Care study (PROSPEC): a randomized controlled trial to evaluate the effectiveness of primary care-based follow-up of localized prostate cancer survivors. BMC Cancer, 2020, 20, 635.	2.6	6

#	Article	IF	Citations
37	Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts. Breast Cancer Research and Treatment, 2020, 181, 423-434.	2.5	14
38	Increased prevalence of BRCA1/2 mutations in women with macrotextured breast implants and anaplastic large cell lymphoma of the breast. Blood, 2020, 136, 1368-1372.	1.4	27
39	Risk of benign meningioma after childhood cancer in the DCOG-LATER cohort: contributions of radiation dose, exposed cranial volume, and age. Neuro-Oncology, 2019, 21, 392-403.	1.2	39
40	Radiation Exposure From Pediatric CT Scans and Subsequent Cancer Risk in the Netherlands. Journal of the National Cancer Institute, 2019, 111, 256-263.	6.3	218
41	Risk of cancer in children and young adults conceived by assisted reproductive technology. Human Reproduction, 2019, 34, 740-750.	0.9	39
42	EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy. Clinical Cancer Research, 2019, 25, 4351-4362.	7.0	33
43	Response to WollschlÃger, Blettner, and Pokora. Journal of the National Cancer Institute, 2019, 111, 1002-1003.	6.3	2
44	Long-Term Risk of Skin Cancer Among Childhood Cancer Survivors: A DCOG-LATER Cohort Study. Journal of the National Cancer Institute, 2019, 111, 845-853.	6.3	19
45	Prediction and clinical utility of a contralateral breast cancer risk model. Breast Cancer Research, 2019, 21, 144.	5.0	24
46	Risk factors for metachronous contralateral breast cancer: A systematic review and meta-analysis. Breast, 2019, 44, 1-14.	2.2	42
47	Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma. Blood, 2019, 133, 1130-1139.	1.4	29
48	Radiation Dose-Response for Risk of Myocardial Infarction in Breast Cancer Survivors. International Journal of Radiation Oncology Biology Physics, 2019, 103, 595-604.	0.8	80
49	Cohort Profile: the EPI-CT study: a European pooled epidemiological study to quantify the risk of radiation-induced cancer from paediatric CT. International Journal of Epidemiology, 2019, 48, 379-381g.	1.9	49
50	THE DOSE AND DOSE-RATE EFFECTIVENESS FACTOR (DDREF). Health Physics, 2019, 116, 96-99.	0.5	13
51	Colorectal Adenomas and Cancers After Childhood Cancer Treatment: A DCOG-LATER Record Linkage Study. Journal of the National Cancer Institute, 2018, 110, 758-767.	6.3	24
52	Gas-induced susceptibility artefacts on diffusion-weighted MRI of the rectum at 1.5â€¯T â€“ Effect of applying a micro-enema to improve image quality. European Journal of Radiology, 2018, 99, 131-137.	2.6	53
53	Breast Implants and the Risk of Anaplastic Large-Cell Lymphoma in the Breast. JAMA Oncology, 2018, 4, 335.	7.1	229
54	Macrotextured Breast Implants with Defined Steps to Minimize Bacterial Contamination around the Device. Plastic and Reconstructive Surgery, 2018, 142, 590e-591e.	1.4	3

#	Article	IF	Citations
55	Inflammation markers and cognitive performance in breast cancer survivors 20 years after completion of chemotherapy: a cohort study. Breast Cancer Research, 2018, 20, 135.	5.0	94
56	Indirect adjustment of relative risks of an exposure with multiple categories for an unmeasured confounder. Annals of Epidemiology, 2018, 28, 801-807.	1.9	7
57	Rationale and design of a cohort study on primary ovarian insufficiency in female survivors of Hodgkinâ€™s lymphoma: influence on long-term adverse effects (SOPHIA). BMJ Open, 2018, 8, e018120.	1.9	3
58	Mild Cognitive Impairment and Dementia Show Contrasting Associations with Risk of Cancer. Neuroepidemiology, 2018, 50, 207-215.	2.3	13
59	Considerations on the use of the terms radiosensitivity and radiosusceptibility. Journal of Radiological Protection, 2018, 38, N25-N29.	1.1	9
60	Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer. British Journal of Cancer, 2018, 119, 408-418.	6.4	50
61	Cardiovascular disease risk after treatment-induced primary ovarian insufficiency in female survivors of Hodgkin lymphoma.. Journal of Clinical Oncology, 2018, 36, 114-114.	1.6	0
62	Stomach Cancer Following Hodgkin Lymphoma, Testicular Cancer and Cervical Cancer: A Pooled Analysis of Three International Studies with a Focus on Radiation Effects. Radiation Research, 2017, 187, 186.	1.5	13
63	Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood, 2017, 129, 2257-2265.	1.4	169
64	Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma: Influence of Gonadal Hormone Exposure. International Journal of Radiation Oncology Biology Physics, 2017, 99, 843-853.	0.8	36
65	Long-term prognosis of young breast cancer patients (â‰¤40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study. BMJ Open, 2017, 7, e017842.	1.9	11
66	Retrospective methods to estimate radiation dose at the site of breast cancer development after Hodgkin lymphoma radiotherapy. Clinical and Translational Radiation Oncology, 2017, 7, 20-27.	1.7	6
67	Trends and patterns of computed tomography scan use among children in The Netherlands: 1990â€“2012. European Radiology, 2017, 27, 2426-2433.	4.5	13
68	Is there Unmeasured Indication Bias in Radiation-Related Cancer Risk Estimates from Studies of Computed Tomography?. Radiation Research, 2017, 189, 128.	1.5	17
69	Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy. Journal of Clinical Oncology, 2017, 35, 2288-2298.	1.6	163
70	Confounding of the association between radiation exposure from CT scans and risk of leukemia and brain tumors by cancer susceptibility syndromes. Journal of Radiological Protection, 2016, 36, 953-974.	1.1	25
71	High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer. Molecular Cancer Therapeutics, 2016, 15, 190-198.	4.1	46
72	Differences in the carcinogenic evaluation of glyphosate between the International Agency for Research on Cancer (IARC) and the European Food Safety Authority (EFSA). Journal of Epidemiology and Community Health, 2016, 70, 741-745.	3.7	138

#	Article	IF	Citations
73	Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERÎ± in Tamoxifen-Associated Endometrial Carcinomas. Cancer Research, 2016, 76, 3773-3784.	0.9	30
74	Increased pancreatic cancer risk following radiotherapy for testicular cancer. British Journal of Cancer, 2016, 115, 901-908.	6.4	30
75	Ovarian Stimulation for In Vitro Fertilization and Long-term Risk of Breast Cancer. JAMA - Journal of the American Medical Association, 2016, 316, 300.	7.4	63
76	Ovarian Stimulation for In Vitro Fertilization and Long-term Risk of Breast Cancer. Obstetrical and Gynecological Survey, 2016, 71, 601-602.	0.4	0
77	Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. Journal of Clinical Oncology, 2016, 34, 235-243.	1.6	339
78	Confounding of the Association between Radiation Exposure from CT Scans and Risk of Leukemia and Brain Tumors by Cancer Susceptibility Syndromes. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 114-126.	2.5	5
79	Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation. International Journal of Cancer, 2015, 136, 1434-1444.	5.1	64
80	EPI-CT: design, challenges and epidemiological methods of an international study on cancer risk after paediatric and young adult CT. Journal of Radiological Protection, 2015, 35, 611-628.	1.1	48
81	Implementation of a Standardized HIPEC Protocol Improves Outcome for Peritoneal Malignancy. World Journal of Surgery, 2015, 39, 453-460.	1.6	45
82	IARC Monographs: 40 Years of Evaluating Carcinogenic Hazards to Humans. Environmental Health Perspectives, 2015, 123, 507-514.	6.0	86
83	Risk for Valvular Heart Disease After Treatment for Hodgkin Lymphoma. Journal of the National Cancer Institute, 2015, 107, .	6.3	224
84	Breast Cancers with aBRCA1-like DNA Copy Number Profile Recur Less Often Than Expected after High-Dose Alkylating Chemotherapy. Clinical Cancer Research, 2015, 21, 763-770.	7.0	34
85	Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13. BMC Cancer, 2015, 15, 588.	2.6	24
86	Prediction of Hearing Loss Due to Cisplatin Chemoradiotherapy. JAMA Otolaryngology - Head and Neck Surgery, 2015, 141, 810.	2.2	20
87	Response to Tarone and McLaughlin: RE: Mortality from solid tumors in the updated NCI formaldehyde worker cohort. American Journal of Industrial Medicine, 2014, 57, 488-489.	2.1	2
88	Long-term hearing loss after chemoradiation in patients with head and neck cancer. Laryngoscope, 2014, 124, 2720-2725.	2.0	20
89	Leukemia and brain tumors among children after radiation exposure from CT scans: design and methodological opportunities of the Dutch Pediatric CT Study. European Journal of Epidemiology, 2014, 29, 293-301.	5.7	40
90	Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Research, 2014, 16, R47.	5.0	86

#	Article	IF	Citations
91	Oral and oropharyngeal squamous cell carcinoma in young patients: The Netherlands Cancer Institute experience. Head and Neck, 2013, 35, 94-102.	2.0	24
92	CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment. Breast Cancer Research and Treatment, 2013, 139, 649-655.	2.5	21
93	Surgical treatment results of intestinal and diffuse type gastric cancer. Implications for a differentiated therapeutic approach?. European Journal of Surgical Oncology, 2013, 39, 686-693.	1.0	40
94	Platform comparisons for identification of breast cancers with a BRCA-like copy number profile. Breast Cancer Research and Treatment, 2013, 139, 317-327.	2.5	20
95	Can extranodal spread in head and neck cancer be detected on MR imaging. Oral Oncology, 2013, 49, 626-633.	1.5	33
96	Mortality from solid tumors among workers in formaldehyde industries: An update of the NCI cohort. American Journal of Industrial Medicine, 2013, 56, 1015-1026.	2.1	41
97	Stomach Cancer Risk After Treatment for Hodgkin Lymphoma. Journal of Clinical Oncology, 2013, 31, 3369-3377.	1.6	96
98	Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ, The, 2012, 345, e5660-e5660.	6.0	186
99	CT scans in childhood and risk of leukaemia and brain tumours. Lancet, The, 2012, 380, 1736.	13.7	12
100	Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer. Breast, 2012, 21, 769-778.	2.2	19
101	Fiveâ€year quality of life results of the randomized clinical phase III (RADPLAT) trial, comparing concomitant intraâ€arterial versus intravenous chemoradiotherapy in locally advanced head and neck cancer. Head and Neck, 2012, 34, 974-980.	2.0	43
102	Preoperative imaging and surgical margins in maxillectomy patients. Head and Neck, 2012, 34, 1652-1656.	2.0	22
103	Tumor volume as prognostic factor in chemoradiation for advanced head and neck cancer. Head and Neck, 2011, 33, 375-382.	2.0	88
104	A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer. British Journal of Cancer, 2011, 104, 1913-1919.	6.4	45
105	PKA-induced phosphorylation of ERÎ± at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Research and Treatment, 2011, 125, 1-12.	2.5	49
106	Flexible modeling of the cumulative effects of timeâ€dependent exposures on the hazard. Statistics in Medicine, 2011, 30, 197-197.	1.6	1
107	Intra-arterial chemotherapy for head and neck cancer. Cancer, 2011, 117, 874-874.	4.1	6
108	Cardiac Function in 5-Year Survivors of Childhood Cancerâ€”Reply. Archives of Internal Medicine, 2011, 171, 264.	3.8	1

#	Article	IF	Citations
109	An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Annals of Oncology, 2011, 22, 1561-1570.	1.2	150
110	Ligands of Epidermal Growth Factor Receptor and the Insulin-Like Growth Factor Family as Serum Biomarkers for Response to Epidermal Growth Factor Receptor Inhibitors in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 1939-1948.	1.1	25
111	Low level alcohol intake, cigarette smoking and risk of breast cancer in Asian-American women. Breast Cancer Research and Treatment, 2010, 120, 203-210.	2.5	26
112	The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Research and Treatment, 2010, 120, 655-661.	2.5	242
113	Letter to the editor: â€œIs preoperative ultrasonography accurate in measuring tumor thickness and predicting the incidence of cervical metastasis in oral cancer?â€• Oral Oncology, 2010, 46, 627.	1.5	0
114	Intraâ€arterial versus intravenous chemoradiation for advanced head and neck cancer: Results of a randomized phase 3 trial. Cancer, 2010, 116, 2159-2165.	4.1	75
115	Radiation Pneumonitis After Hypofractionated Radiotherapy: Evaluation of the LQ(L) Model and Different Dose Parameters. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1596-1603.	0.8	59
116	Occupational Exposure to Formaldehyde, Hematotoxicity and Leukemia-Specific Chromosome Changes in Cultured Myeloid Progenitor Cells â€“ Response. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1884-1885.	2.5	10
117	RE: A further plea for adherence to the principles underlying science in general and the epidemiologic enterprise in particular. International Journal of Epidemiology, 2010, 39, 1677-1679.	1.9	4
118	Response: Re: Mortality From Lymphohematopoietic Malignancies and Brain Cancer Among Embalmers Exposed to Formaldehyde. Journal of the National Cancer Institute, 2010, 102, 1519-1520.	6.3	1
119	Cardiac Function in 5-Year Survivors of Childhood Cancer. Archives of Internal Medicine, 2010, 170, 1247-55.	3.8	144
120	Occupational Exposure to Formaldehyde, Hematotoxicity, and Leukemia-Specific Chromosome Changes in Cultured Myeloid Progenitor Cells. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 80-88.	2.5	160
121	Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. European Journal of Cancer, 2010, 46, 1382-1391.	2.8	94
122	HPV and high-risk gene expression profiles predict response to chemoradiotherapy in head and neck cancer, independent of clinical factors. Radiotherapy and Oncology, 2010, 95, 365-370.	0.6	36
123	Mortality From Lymphohematopoietic Malignancies Among Workers in Formaldehyde Industries: The National Cancer Institute Cohort. Journal of the National Cancer Institute, 2009, 101, 751-761.	6.3	187
124	Estrogen Receptor-Î± Phosphorylation at Serine-118 and Tamoxifen Response in Breast Cancer. Journal of the National Cancer Institute, 2009, 101, 1725-1729.	6.3	55
125	Mortality From Lymphohematopoietic Malignancies and Brain Cancer Among Embalmers Exposed to Formaldehyde. Journal of the National Cancer Institute, 2009, 101, 1696-1708.	6.3	193
126	Radiotherapy in laryngeal carcinoma: Can a panel of 13 markers predict response?. Laryngoscope, 2009, 119, 316-322.	2.0	21

#	Article	IF	Citations
127	Roles of Radiation Dose and Chemotherapy in the Etiology of Stomach Cancer as a Second Malignancy. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1420-1429.	0.8	92
128	Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. Breast Cancer Research and Treatment, 2009, 113, 275-283.	2.5	56
129	Phosphorylation of the oestrogen receptor Î± at serine 305 and prediction of tamoxifen resistance in breast cancer. Journal of Pathology, 2009, 217, 372-379.	4.5	54
130	Radiation pneumonitis in patients treated for malignant pulmonary lesions with hypofractionated radiation therapy. Radiotherapy and Oncology, 2009, 91, 307-313.	0.6	133
131	Using tensor product splines in modeling exposureâ€“timeâ€“response relationships: Application to the Colorado Plateau Uranium Miners cohort. Statistics in Medicine, 2008, 27, 5484-5496.	1.6	27
132	Refinement of breast cancer classification by molecular characterization of histological special types. Journal of Pathology, 2008, 216, 141-150.	4.5	471
133	Polymorphisms in DNA repair genes, ionizing radiation exposure and risk of breast cancer in U.S. Radiologic technologists. International Journal of Cancer, 2008, 122, 177-182.	5.1	58
134	Occupation and breast cancer risk among Shanghai women in a populationâ€based cohort study. American Journal of Industrial Medicine, 2008, 51, 100-110.	2.1	23
135	EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Research, 2008, 10, R109.	5.0	106
136	International study of factors affecting human chromosome translocations. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2008, 652, 112-121.	1.7	120
137	Risk of Cataract after Exposure to Low Doses of Ionizing Radiation: A 20-Year Prospective Cohort Study among US Radiologic Technologists. American Journal of Epidemiology, 2008, 168, 620-631.	3.4	318
138	Roles of Radiotherapy and Chemotherapy in the Development of Contralateral Breast Cancer. Journal of Clinical Oncology, 2008, 26, 5561-5568.	1.6	96
139	Treatment-related risk factors for premature menopause following Hodgkin lymphoma. Blood, 2008, 111, 101-108.	1.4	125
140	Cigarette Smoking and Cancer Risk: Modeling Total Exposure and Intensity. American Journal of Epidemiology, 2007, 166, 479-489.	3.4	73
141	Smoking Cigarettes before First Childbirth and Risk of Breast Cancer. American Journal of Epidemiology, 2007, 166, 55-61.	3.4	43
142	Polymorphisms in Apoptosis- and Proliferation-Related Genes, Ionizing Radiation Exposure, and Risk of Breast Cancer among U.S. Radiologic Technologists. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2000-2007.	2.5	45
143	Retrospective Biodosimetry among United States Radiologic Technologists. Radiation Research, 2007, 167, 727-734.	1.5	36
144	A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer. Cancer Cell, 2007, 12, 395-402.	16.8	1,471

#	Article	IF	Citations
145	Estimating Historical Radiation Doses to a Cohort of U.S. Radiologic Technologists. Radiation Research, 2006, 166, 174-192.	1.5	72
146	Relationship between clinical factors and the incidence of toxicity after intra-arterial chemoradiation for head and neck cancer. Radiotherapy and Oncology, 2006, 81, 143-150.	0.6	32
147	Interventional radiography and mortality risks in U.S. radiologic technologists. Pediatric Radiology, 2006, 36, 113-120.	2.0	16
148	Breast cancer incidence in U.S. radiologic technologists. Cancer, 2006, 106, 2707-2715.	4.1	80
149	Thyroid cancer and employment as a radiologic technologist. International Journal of Cancer, 2006, 119, 1940-1945.	5.1	42
150	Lung cancer risk among US radiologic technologists, 1983-1998. International Journal of Cancer, 2006, 119, 2481-2486.	5.1	11
151	Nonmelanoma skin cancer in relation to ionizing radiation exposure among U.S. radiologic technologists. International Journal of Cancer, 2005, 115, 828-834.	5.1	79
152	Incidence of haematopoietic malignancies in US radiologic technologists. Occupational and Environmental Medicine, 2005, 62, 861-867.	2.8	58
153	Re: â€œMortality from Solid Cancers among Workers in Formaldehyde Industriesâ€• American Journal of Epidemiology, 2005, 161, 1089-1090.	3.4	14
154	DNA damage among thyroid cancer and multiple cancer cases, controls, and long-lived individuals. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2005, 586, 173-188.	1.7	41
155	Meeting Report: Summary of IARC Monographs on Formaldehyde, 2-Butoxyethanol, and 1- tert -Butoxy-2-Propanol. Environmental Health Perspectives, 2005, 113, 1205-1208.	6.0	305
156	Particulate air pollution and nonfatal cardiac events. Part I. Air pollution, personal activities, and onset of myocardial infarction in a case-crossover study. Research Report (health Effects Institute), 2005, , 1-66; discussion 67-82, 141-8.	1.6	34
157	Mortality from Solid Cancers among Workers in Formaldehyde Industries. American Journal of Epidemiology, 2004, 159, 1117-1130.	3.4	264
158	Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes. BMC Cancer, 2004, 4, 9.	2.6	73
159	Advice on formaldehyde and glycol ethers. Lancet Oncology, The, 2004, 5, 528.	10.7	50
160	Cancer incidence in the U.S. radiologic technologists health study, 1983-1998. Cancer, 2003, 97, 3080-3089.	4.1	178
161	Cancer and other causes of mortality among radiologic technologists in the United States. International Journal of Cancer, 2003, 103, 259-267.	5.1	99
162	Risk of melanoma among radiologic technologists in the United States. International Journal of Cancer, 2003, 103, 556-562.	5.1	65

#	Article	IF	Citations
163	Site-Specific Cancer Incidence and Mortality after Cerebral Angiography with Radioactive Thorotrast. Radiation Research, 2003, 160, 691-706.	1.5	60
164	Mortality From Lymphohematopoietic Malignancies Among Workers in Formaldehyde Industries. Journal of the National Cancer Institute, 2003, 95, 1615-1623.	6.3	176
165	Mortality from Diseases of the Circulatory System in Radiologic Technologists in the United States. American Journal of Epidemiology, 2003, 157, 239-248.	3.4	77
166	Re: Population-Based, Case-Control Study of HER2 Genetic Polymorphism and Breast Cancer Risk. Journal of the National Cancer Institute, 2003, 95, 1251-1252.	6.3	9
167	Breast Cancer Mortality Among Female Radiologic Technologists in the United States. Journal of the National Cancer Institute, 2002, 94, 943-948.	6.3	40
168	A Case-Control Study of Dietary Phytoestrogens and Testicular Cancer Risk. Nutrition and Cancer, 2002, 44, 44-51.	2.0	41
169	The exposure-time-response relationship between occupational asbestos exposure and lung cancer in two German case-control studies*. American Journal of Industrial Medicine, 2002, 41, 89-97.	2.1	46
170	Occupational and environmental risks of spontaneous abortions around a smelter. American Journal of Industrial Medicine, 2002, 41, 131-138.	2.1	7
171	Using splines to analyse latency in the Colorado Plateau uranium miners cohort. Journal of Epidemiology and Biostatistics, 2001, 6, 417-424.	0.4	32
172	The use of sliding time windows for the exploratory analysis of temporal effects of smoking histories on lung cancer risk. Statistics in Medicine, 2000, 19, 2185-2194.	1.6	29
173	Analysis of Exposure-Time-Response Relationships Using a Spline Weight Function. Biometrics, 2000, 56, 1105-1108.	1.4	58